Considering that the hyperphosphatemia is a common metabolic disorder for pre‐dialysis CKD patients, this study provides a novel immunoregulation strategy for AVFs under CKD condition, as suppressing BACE2‐mediated VEGFR3 cleavage to recover a functionally competent lymphatic network is a potential target. The gene discussed is BACE2; the disease is hyperphosphatemia.